Compare CMPX & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPX | LAB |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.0M | 347.5M |
| IPO Year | 2020 | 2008 |
| Metric | CMPX | LAB |
|---|---|---|
| Price | $2.09 | $0.83 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 1 |
| Target Price | ★ $14.57 | $1.35 |
| AVG Volume (30 Days) | ★ 3.8M | 3.6M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.54 |
| EPS | N/A | ★ 0.33 |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $934.41 | $2.63 |
| P/E Ratio | ★ N/A | $2.50 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.61 | $0.79 |
| 52 Week High | $6.88 | $1.72 |
| Indicator | CMPX | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 40.68 | 38.67 |
| Support Level | $1.88 | N/A |
| Resistance Level | $2.47 | $1.02 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 31.82 | 7.94 |
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.